0000000000247685

AUTHOR

Ragnar Westerling

showing 2 related works from this author

The timing of introduction of pharmaceutical innovations in seven European countries

2014

RATIONALE, AIMS AND OBJECTIVES: Differences in the performance of medical care may be due to variation in the introduction and diffusion of medical innovations. The objective of this paper is to compare seven European countries (United Kingdom, the Netherlands, West Germany, France, Spain, Estonia and Sweden) with regard to the year of introduction of six specific pharmaceutical innovations (antiretroviral drugs, cimetidine, tamoxifen, cisplatin, oxalaplatin and cyclosporin) that may have had important population health impacts. METHODS: We collected information on introduction and further diffusion of drugs using searches in the national and international literature, and questionnaires to …

medicine.medical_specialtyTime FactorsAlternative medicinePopulation healthpharmaceuticalsMedical careWest germanyoutcome measuresNursingquality of careSurveys and QuestionnairesInternational literaturemedicineHumansPharmaceutical innovationsSales statisticsDrug ApprovalQuality of Health Carebusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthOriginal ArticlesmortalityClinical trialEuropePharmaceutical Preparationsmedical careDiffusion of Innovationbusinesshealth systemsDemographyJournal of Evaluation in Clinical Practice
researchProduct

Innovations in medical care and mortality trends from four circulatory diseases between 1970 and 2005

2013

Background: Governments have identified innovation in pharmaceuticals and medical technology as a priority for health policy. Although the contribution of medical care to health has been studied extensively in clinical settings, much less is known about its contribution to population health. We examine how innovations in the management of four circulatory disorders have influenced trends in cause-specific mortality at the population level. Methods: Based on literature reviews, we selected six medical innovations with proven effectiveness against hypertension, ischaemic heart disease, heart failure and cerebrovascular disease. We combined data on the timing of these innovations and cause-spe…

Estoniamedicine.medical_specialtyTime FactorsPopulation levelPsychological interventionMyocardial IschemiaPopulation healthMedical careSDG 3 - Good Health and Well-beingEnvironmental healthCause of DeathGermanySurveys and QuestionnairesMedicineHumansMortalityIntensive care medicineMortality trendsHealth policyNetherlandsHeart FailureSwedenbusiness.industryTherapies InvestigationalPublic Health Environmental and Occupational HealthHealth technologymedicine.diseaseUnited KingdomEuropeCerebrovascular DisordersSpainHeart failureHypertensionFrancebusinessEuropean Journal of Public Health
researchProduct